

RNS Number : 6923G
 Redx Pharma plc
 17 November 2022

REDX PHARMA PLC
 ("Redx" or "the Company")

Redx to Present Poster on the Potential of RXC008 in Crohn's Disease at the Inflammatory Bowel Disease Nordic Conference

Alderley Park, UK, 17 November 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that it will present a poster on the effect of RXC008 in suppressing fibrosis and tissue injury in pre-clinical models of Crohn's disease at the Inflammatory Bowel Disease Nordic (IBD Nordic) Conference (23-25 November 2022, Malmo Sweden).

RXC008 is a potent, selective, GI-targeted ROCK1/2 inhibitor currently at pre-IND stage for the treatment of fibrostenotic Crohn's disease. The poster at IBD Nordic will present results from adoptive transfer and chronic dextran sulphate sodium (DSS) modelling studies which show that RXC008 can suppress fibrosis and attenuate tissue injury in animal models of GI-fibrosis and has the potential to be developed as a novel therapy to inhibit fibrotic stricture formation in Crohn's disease. The results presented in the poster are from a research collaboration between Redx and scientists at Belgium's Ghent University, where non-invasive magnetic resonance imaging (MRI) texture analysis and histology were used in the models to assess reduction in tissue injury and fibrosis. Redx aims to use MRI translationally in future studies with RXC008 given its ability to monitor the effectiveness of RXC008 without the need for an invasive biopsy.

Title: RXC008, a GI-targeted ROCK Inhibitor, Suppresses Fibrosis and Tissue Injury in Models of Crohn's Disease

Day/Date: Wednesday, 23 November 2022

Time: 17:45 CET

A copy of the poster will be made available on the Company's website following the presentation at: <https://www.redxpharma.com/scientific-publications/>

For further information, please contact:

Redx Pharma Plc
UK Headquarters

Caitlin Pearson, Head of Communications
ir@redxpharma.com

Lisa Anson, Chief Executive Officer

US Office

Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser)

Matt Davis/ Adam Dawes

WG Partners LLP (Joint Broker)

Claes Spång/ Satheesh Nadarajah/ David Wilson

Panmure Gordon (UK) Limited (Joint Broker)

Rupert Dearden/ Freddy Crossley/ Emma Earl

FTI Consulting

Simon Conway/ Ciara Martin

T: +44 (0)1625 469 918

T: +44 (0)203 368 3550

T: +44 (0)203 705 9330

T: +44 (0)207 886 2500

T: +44 (0)203 727 1000

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRABKABPKBDBODD